115 related articles for article (PubMed ID: 20850977)
1. The synthesis and biologic evaluation of anti-platelet and cytotoxic β-nitrostyrenes.
Hsieh PW; Chang YT; Chuang WY; Shih HC; Chiang SZ; Wu CC
Bioorg Med Chem; 2010 Nov; 18(21):7621-7. PubMed ID: 20850977
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and pharmacological evaluation of novel beta-nitrostyrene derivatives as tyrosine kinase inhibitors with potent antiplatelet activity.
Wang WY; Hsieh PW; Wu YC; Wu CC
Biochem Pharmacol; 2007 Aug; 74(4):601-11. PubMed ID: 17601492
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the interactions between metastatic human breast cancer cells and platelets by β-nitrostyrene derivatives.
Wei CK; Chang FR; Hsieh PW; Wu CC
Life Sci; 2015 Dec; 143():147-55. PubMed ID: 26546721
[TBL] [Abstract][Full Text] [Related]
4. Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-beta-nitrostyrene, a novel tyrosine kinase inhibitor.
Wang WY; Wu YC; Wu CC
Mol Pharmacol; 2006 Oct; 70(4):1380-9. PubMed ID: 16837624
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and anti-platelet evaluation of 2-benzoylaminobenzoate analogs.
Hsieh PW; Chiang SZ; Wu CC; Lo YC; Shih YT; Wu YC
Bioorg Med Chem; 2008 May; 16(10):5803-14. PubMed ID: 18407506
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of antiplatelet activity of trihydroxychalcone derivatives.
Zhao LM; Jin HS; Sun LP; Piao HR; Quan ZS
Bioorg Med Chem Lett; 2005 Nov; 15(22):5027-9. PubMed ID: 16169724
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationship studies on chalcone derivatives: potent inhibition of platelet aggregation.
Ko HH; Hsieh HK; Liu CT; Lin HC; Teng CM; Lin CN
J Pharm Pharmacol; 2004 Oct; 56(10):1333-7. PubMed ID: 15482650
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of platelet aggregation inhibitory activity of some 3-phenyl-pyrroloquinazolinones.
Ferlin MG; Borgo C; Deana R
Eur J Med Chem; 2012 Feb; 48():275-83. PubMed ID: 22236469
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and inhibitory activities on platelet aggregation of some flavonoid analogues.
Göker H; Tunçbilek M; Leoncini G; Buzzi E; Mazzei M; Rolland Y; Ertan R
Arzneimittelforschung; 1995 Feb; 45(2):150-5. PubMed ID: 7710437
[TBL] [Abstract][Full Text] [Related]
10. The evaluation and structure-activity relationships of 2-benzoylaminobenzoic esters and their analogues as anti-inflammatory and anti-platelet aggregation agents.
Hsieh PW; Hwang TL; Wu CC; Chiang SZ; Wu CI; Wu YC
Bioorg Med Chem Lett; 2007 Mar; 17(6):1812-7. PubMed ID: 17197180
[TBL] [Abstract][Full Text] [Related]
11. Tricyclic pharmacophore-based molecules as novel integrin alpha(v)beta3 antagonists. Part 2: synthesis of potent alpha(v)beta3/alpha(IIb)beta3 dual antagonists.
Ishikawa M; Kubota D; Yamamoto M; Kuroda C; Iguchi M; Koyanagi A; Murakami S; Ajito K
Bioorg Med Chem; 2006 Apr; 14(7):2109-30. PubMed ID: 16309912
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and anti-platelet activity of obovatol derivatives.
Kwak JH; Lee S; Park ES; In JK; Song J; Kim YJ; Choi NS; Lee H; Yun YP; Hong JT; Kwak YS; Min KH; Jung JK
Arch Pharm Res; 2011 Jul; 34(7):1107-12. PubMed ID: 21811917
[TBL] [Abstract][Full Text] [Related]
13. A novel anti-platelet aggregation tripeptide from Agkistrodon acutus venom: isolation and characterization.
Kong Y; Huo JL; Xu W; Xiong J; Li YM; Wu WT
Toxicon; 2009 Aug; 54(2):103-9. PubMed ID: 19345702
[TBL] [Abstract][Full Text] [Related]
14. Tricyclic pharmacophore-based molecules as novel integrin alpha(v)beta3 antagonists. Part 1: design and synthesis of a lead compound exhibiting alpha(v)beta3/alpha(IIb)beta3 dual antagonistic activity.
Kubota D; Ishikawa M; Yamamoto M; Murakami S; Hachisu M; Katano K; Ajito K
Bioorg Med Chem; 2006 Apr; 14(7):2089-108. PubMed ID: 16309911
[TBL] [Abstract][Full Text] [Related]
15. Construction of drug screening cell model and application to new compounds inhibiting FITC-fibrinogen binding to CHO cells expressing human alphaIIbbeta3.
Yang J; Yao J; Chen J; Wang XN; Zhu TY; Chen LL; Chu P
Eur J Pharmacol; 2009 Sep; 618(1-3):1-8. PubMed ID: 19619528
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of baicalein derivatives as potential anti-aggregatory and anti-inflammatory agents.
Huang WH; Lee AR; Chien PY; Chou TC
J Pharm Pharmacol; 2005 Feb; 57(2):219-25. PubMed ID: 15720786
[TBL] [Abstract][Full Text] [Related]
17. New platelet fibrinogen receptor glycoprotein IIb-IIIa antagonists: orally active series of N-alkylated amidines with a 6,6-bicyclic template.
Okumura K; Shimazaki T; Aoki Y; Yamashita H; Tanaka E; Banba S; Yazawa K; Kibayashi K; Banno H
J Med Chem; 1998 Oct; 41(21):4036-52. PubMed ID: 9767641
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, antiplatelet and vasorelaxing activities of xanthone derivatives.
Lin KW; Fang SC; Hung CF; Shieh BJ; Yang SC; Teng CM; Lin CN
Arch Pharm (Weinheim); 2009 Jan; 342(1):19-26. PubMed ID: 19035386
[TBL] [Abstract][Full Text] [Related]
19. Novel thienylacylhydrazone derivatives inhibit platelet aggregation through cyclic nucleotides modulation and thromboxane A2 synthesis inhibition.
Brito FC; Kummerle AE; Lugnier C; Fraga CA; Barreiro EJ; Miranda AL
Eur J Pharmacol; 2010 Jul; 638(1-3):5-12. PubMed ID: 20412790
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of N6-alkyl(aryl)-2-alkyl(aryl)thioadenosines as antiplatelet agents.
Liu G; Xu J; Chen N; Zhang S; Ding Z; Du H
Eur J Med Chem; 2012 Jul; 53():114-23. PubMed ID: 22531380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
